PARIS, March 25 /PRNewswire/ --
The investor meeting relating to the 2008 earnings and 2009 outlook has been webcasted. The presentation is available in English from the following link:
Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% (gross) of its sales to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.
In 2008, Stallergenes had sales of EUR 171 million and provided desensitization treatments to more than 500,000 patients.
Euronext Paris (Compartment B) SBF 120. ISIN Code: FR0000065674 Reuters Code: GEN.PA Bloomberg Code: GEN.FP
Additional financial information is available at http://www.stallergenes.com
Lucile de FRAGUIER, PAVIE FINANCE, T : +33(0)1-42-15-04-39, mailto:firstname.lastname@example.org